Research programme: Alzheimer's disease therapies - Bayer
Latest Information Update: 18 Apr 2007
At a glance
- Originator Bayer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 28 Feb 2001 Preclinical development for Alzheimer's disease in Europe (Unknown route)
- 28 Feb 2001 Preclinical development for Alzheimer's disease in USA (Unknown route)